Literature DB >> 23988715

Nanoclusters self-assembled from conformation-stabilized influenza M2e as broadly cross-protective influenza vaccines.

Li Wang1, Annie Hess2, Timothy Z Chang2, Ying-Chun Wang1, Julie A Champion3, Richard W Compans4, Bao-Zhong Wang5.   

Abstract

Influenza vaccines with broad cross-protection are urgently needed. The highly conserved ectodomain of the influenza matrix protein 2 (M2e) can be a promising candidate if its low immunogenicity was overcome. In this study, we generated protein nanoclusters self-assembled from conformation-stabilized M2e tetramers (tM2e) to improve its immunogenicity. The resulting nanoclusters showed an average hydrodynamic diameter of 227 nm. Vaccination with the nanoclusters by an intranasal route elicited high levels of serum antigen-specific IgG in mice (approximately 100-fold higher than that obtained with soluble tM2e), as well as antigen-specific T cell and mucosal antibody responses. The immunity conferred complete protection against lethal challenge with homo- as well as heterosubtypic viruses. These results demonstrate that nanoclusters assembled from conformation-stabilized M2e are promising as a potential universal influenza A vaccine. Self-assembly into nanoclusters represents a novel approach for increasing the immunogenicity of vaccine antigens. FROM THE CLINICAL EDITOR: In order to develop more effective influenza vaccination, the highly conserved ectodomain of M2e could be a promising candidate. Unfortunately, it is a weak antigen for vaccination purposes. In this study, self-assembled protein nanoclusters of tM2e were generated and tested. The nanoclusters demonstrated superior vaccination properties, with complete protection against lethal challenge in the studied rodent model, raising hope for the introduction of similar vaccines to challenge human influenza outbreaks.
© 2014.

Entities:  

Keywords:  Cross protection; Matrix protein 2 (M2); Nanocluster

Mesh:

Substances:

Year:  2013        PMID: 23988715      PMCID: PMC3948190          DOI: 10.1016/j.nano.2013.08.005

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  46 in total

1.  Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines.

Authors:  Yasuko Asahi; Tomoki Yoshikawa; Izumi Watanabe; Takuya Iwasaki; Hideki Hasegawa; Yuko Sato; Shin-ichiro Shimada; Masanobu Nanno; Yoshiaki Matsuoka; Makoto Ohwaki; Yoichiro Iwakura; Yujiro Suzuki; Chikara Aizawa; Tetutaro Sata; Takeshi Kurata; Shin-ichi Tamura
Journal:  J Immunol       Date:  2002-03-15       Impact factor: 5.422

2.  The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.

Authors:  Marina De Filette; Anna Ramne; Ashley Birkett; Nils Lycke; Björn Löwenadler; Willy Min Jou; Xavier Saelens; Walter Fiers
Journal:  Vaccine       Date:  2005-08-31       Impact factor: 3.641

3.  Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design.

Authors:  Juliana Bessa; Nicole Schmitz; Heather J Hinton; Katrin Schwarz; Andrea Jegerlehner; Martin F Bachmann
Journal:  Eur J Immunol       Date:  2008-01       Impact factor: 5.532

4.  Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus.

Authors:  Tong-Ming Fu; Daniel C Freed; Melanie S Horton; Jiang Fan; Michael P Citron; Joseph G Joyce; Victor M Garsky; Danilo R Casimiro; Qinjian Zhao; John W Shiver; Xiaoping Liang
Journal:  Virology       Date:  2008-12-13       Impact factor: 3.616

5.  Improved design and intranasal delivery of an M2e-based human influenza A vaccine.

Authors:  Marina De Filette; Walter Fiers; Wouter Martens; Ashley Birkett; Anna Ramne; Björn Löwenadler; Nils Lycke; Willy Min Jou; Xavier Saelens
Journal:  Vaccine       Date:  2006-06-12       Impact factor: 3.641

6.  Effects of antibody to the influenza A virus M2 protein on M2 surface expression and virus assembly.

Authors:  P G Hughey; P C Roberts; L J Holsinger; S L Zebedee; R A Lamb; R W Compans
Journal:  Virology       Date:  1995-10-01       Impact factor: 3.616

7.  Antiserum against the conserved nine amino acid N-terminal peptide of influenza A virus matrix protein 2 is not immunoprotective.

Authors:  Marina De Filette; Tine Ysenbaert; Kenny Roose; Michael Schotsaert; Stefan Roels; Els Goossens; Bert Schepens; Walter Fiers; Xavier Saelens
Journal:  J Gen Virol       Date:  2010-10-21       Impact factor: 3.891

8.  Roles of CD4+ T-cell-independent and -dependent antibody responses in the control of influenza virus infection: evidence for noncognate CD4+ T-cell activities that enhance the therapeutic activity of antiviral antibodies.

Authors:  Krystyna Mozdzanowska; Michelle Furchner; Darya Zharikova; Jingqi Feng; Walter Gerhard
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

9.  Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection.

Authors:  Bao-Zhong Wang; Rui Xu; Fu-Shi Quan; Sang-Moo Kang; Li Wang; Richard W Compans
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

10.  Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses.

Authors:  Bao-Zhong Wang; Fu-Shi Quan; Sang-Moo Kang; Jadranka Bozja; Ioanna Skountzou; Richard W Compans
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

View more
  29 in total

Review 1.  Advances in the development of influenza virus vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Rev Drug Discov       Date:  2015-03       Impact factor: 84.694

2.  Heterosubtypic influenza protection elicited by double-layered polypeptide nanoparticles in mice.

Authors:  Lei Deng; Timothy Z Chang; Ye Wang; Song Li; Shelly Wang; Shingo Matsuyama; Guoying Yu; Richard W Compans; Jian-Dong Li; Mark R Prausnitz; Julie A Champion; Bao-Zhong Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-31       Impact factor: 11.205

3.  Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge.

Authors:  Lei Deng; Jong R Kim; Timothy Z Chang; Han Zhang; Teena Mohan; Julie A Champion; Bao-Zhong Wang
Journal:  Virology       Date:  2017-06-13       Impact factor: 3.616

4.  Double-Layered M2e-NA Protein Nanoparticle Immunization Induces Broad Cross-Protection against Different Influenza Viruses in Mice.

Authors:  Ye Wang; Lei Deng; Gilbert X Gonzalez; Latika Luthra; Chunhong Dong; Yao Ma; Jun Zou; Sang-Moo Kang; Bao-Zhong Wang
Journal:  Adv Healthc Mater       Date:  2019-12-15       Impact factor: 9.933

5.  Effects of ovalbumin protein nanoparticle vaccine size and coating on dendritic cell processing.

Authors:  Timothy Z Chang; Samantha S Stadmiller; Erika Staskevicius; Julie A Champion
Journal:  Biomater Sci       Date:  2017-01-31       Impact factor: 6.843

6.  Coated protein nanoclusters from influenza H7N9 HA are highly immunogenic and induce robust protective immunity.

Authors:  Li Wang; Timothy Z Chang; Yuan He; Jong R Kim; Shelly Wang; Teena Mohan; Zachary Berman; S Mark Tompkins; Ralph A Tripp; Richard W Compans; Julie A Champion; Bao-Zhong Wang
Journal:  Nanomedicine       Date:  2016-09-10       Impact factor: 5.307

7.  Gold nanoparticles conjugating recombinant influenza hemagglutinin trimers and flagellin enhanced mucosal cellular immunity.

Authors:  Chao Wang; Wandi Zhu; Yuan Luo; Bao-Zhong Wang
Journal:  Nanomedicine       Date:  2018-04-09       Impact factor: 5.307

Review 8.  Universal influenza vaccines: from viruses to nanoparticles.

Authors:  Ye Wang; Lei Deng; Sang-Moo Kang; Bao-Zhong Wang
Journal:  Expert Rev Vaccines       Date:  2018-11-02       Impact factor: 5.217

Review 9.  Biomaterial Strategies for Immunomodulation.

Authors:  Nathan A Hotaling; Li Tang; Darrell J Irvine; Julia E Babensee
Journal:  Annu Rev Biomed Eng       Date:  2015-09-29       Impact factor: 9.590

10.  Intranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains.

Authors:  Chunhong Dong; Ye Wang; Gilbert X Gonzalez; Yao Ma; Yufeng Song; Shelly Wang; Sang-Moo Kang; Richard W Compans; Bao-Zhong Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.